 BOSTON, July 8, 2021 PRNewswire -- Cyclerion Therapeutics, Inc. Nasdaq: CYCN and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerions investigational therapeutics for neurological diseases associated with cognitive impairment. 